Usha Singh1, Deeksha Katoch1, Savleen Kaur1, Mangat Ram Dogra1, Deepak Bansal2, Rakesh Kapoor3. 1. Advanced Eye Centre, Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 2. Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 3. Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Abstract
PURPOSE: To study epidemiology, demographic profile, clinical characteristics, and outcome in pediatric patients with retinoblastoma. METHODS: This was a retrospective review of retinoblastoma patients of a tertiary institute from January 1st 1998 to December 31st 2014. RESULTS: The study included 467 patients (618 eyes) with a mean age of 34.7 ± 24.6 months (median = 30; 15 days to 144 months). Retinoblastoma was bilateral in 151 (32.3%) and there were 61.7% males. Intraocular disease was seen in 301 patients (451 eyes [72.9%]) and extraocular in 166 patients (167 eyes; 27.0%). Out of the 347 (74.3%) who received treatment, primary treatment was chemoreduction in 228 (65.7%) and enucleation in 117 (33.7%), while 25.6% of patients refused treatment and 151 (43.5%) defaulted therapy. Local recurrence was seen in 20 (4.3%), metastasis in 2 (0.4%), and deaths in 13 (2.8%) (average follow-up 28.5 ± 44.4 months). Histopathological high risk features were significantly less in the eyes that received chemoreduction (5.0%) versus primary enucleation (20.8%) (p < 0.0004), but there was no difference in the rate of metastasis, recurrence, and death between the two. CONCLUSIONS: The majority of retinoblastoma patients in our study had advanced disease, and nearly a third had extraocular extension. There were a significant number of therapy refusals and dropouts. Chemoreduction led to a significant decrease in the histopathological risk factors without affecting the outcomes.
PURPOSE: To study epidemiology, demographic profile, clinical characteristics, and outcome in pediatric patients with retinoblastoma. METHODS: This was a retrospective review of retinoblastoma patients of a tertiary institute from January 1st 1998 to December 31st 2014. RESULTS: The study included 467 patients (618 eyes) with a mean age of 34.7 ± 24.6 months (median = 30; 15 days to 144 months). Retinoblastoma was bilateral in 151 (32.3%) and there were 61.7% males. Intraocular disease was seen in 301 patients (451 eyes [72.9%]) and extraocular in 166 patients (167 eyes; 27.0%). Out of the 347 (74.3%) who received treatment, primary treatment was chemoreduction in 228 (65.7%) and enucleation in 117 (33.7%), while 25.6% of patients refused treatment and 151 (43.5%) defaulted therapy. Local recurrence was seen in 20 (4.3%), metastasis in 2 (0.4%), and deaths in 13 (2.8%) (average follow-up 28.5 ± 44.4 months). Histopathological high risk features were significantly less in the eyes that received chemoreduction (5.0%) versus primary enucleation (20.8%) (p < 0.0004), but there was no difference in the rate of metastasis, recurrence, and death between the two. CONCLUSIONS: The majority of retinoblastoma patients in our study had advanced disease, and nearly a third had extraocular extension. There were a significant number of therapy refusals and dropouts. Chemoreduction led to a significant decrease in the histopathological risk factors without affecting the outcomes.
Authors: S Canturk; I Qaddoumi; V Khetan; Z Ma; A Furmanchuk; C B G Antoneli; I Sultan; R Kebudi; T Sharma; C Rodriguez-Galindo; D H Abramson; G L Chantada Journal: Br J Ophthalmol Date: 2010-08-23 Impact factor: 4.638
Authors: Christopher Leander; Ligia C Fu; Armando Peña; Scott C Howard; Carlos Rodriguez-Galindo; Judith A Wilimas; Raul C Ribeiro; Barrett Haik Journal: Pediatr Blood Cancer Date: 2007-11 Impact factor: 3.167
Authors: Nida Zia; Ahmer Hamid; Sundus Iftikhar; Muhammad Hamza Qadri; Anzal Jangda; Muhammad Rahil Khan Journal: Pak J Med Sci Date: 2020-01 Impact factor: 1.088